Preliminary results of a phase 1/2, first-in-human, open-label, dose escalation study of ZL-1211 (anti-Claudin 18.2 mAb) in patients with unresectable or metastatic solid tumors

被引：0
|
作者：
Sharma, Sunil
Starodub, Alexander
Xu, Nong
Chaudhry, Arvind
Sun, Meili
Pelster, Meredith
Fu, Yinjia
Zhang, Xinyu
Huang, Zhao
Liu, Wenyu
Hsu, Karl
机构：
[1] Honor Hlth, Scottsdale, AZ USA
[2] Parkview Canc Inst, Parkview Physician Grp, Cincinnati, OH USA
[3] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Hangzhou, Peoples R China
[4] Summit Canc Centers, Spokane Valley, WA USA
[5] Jinan Cent Hosp, Jinan, Peoples R China
[6] Sarah Cannon Res Inst, Tennessee Oncol, Nashville, TN USA
[7] Zai Lab Shanghai Co Ltd, Shanghai, Peoples R China
[8] Zai Lab Shanghai Co Ltd, R&D Dept, Shanghai, Peoples R China
[9] Zai Lab US LLC, Cambridge, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2537
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Updated results from a phase I, open-label, multicenter, first-in-human study of AMG 404, a checkpoint inhibitor, in patients with advanced solid tumors
    Price, T. J.
    Prenen, H.
    Lugowska, I.
    Falchook, G. S.
    Monzon, J. G.
    Arkenau, H. T.
    Chawla, S. P.
    Hui, M. N.
    Kuboki, Y.
    Dziadziuszko, R.
    Ozawa, Y.
    Fernandez, M. E. Elez
    Lima, C. S. P. Rocha
    Subbiah, V.
    Tan, D. S. W.
    Wang, K.
    Hindoyan, A.
    Shi, W.
    Kistler, M.
    Sadraei, N. Hashemi
    ANNALS OF ONCOLOGY, 2021, 32 : S1440 - S1442
  • [32] A phase I, first-in-human, open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP-1287 administered daily to patients with advanced solid tumors.
    Ben George
    Richards, Donald A.
    Edenfield, William Jeffory
    Warner, Steven L.
    Mouritsen, Lars
    Bishop, Reyna
    Anthony, Stephen Patrick
    Bearss, David
    Vogelzang, Nicholas J.
    Whatcott, Clifford
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [33] An open-label, multicentre, dose-escalation, first-in-human phase I study to evaluate safety, tolerability and antineoplastic activity of OATD-02 (dual arginase 1 and arginase 2 inhibitor) in patients with selected advanced and/or metastatic solid tumors
    Dudek, M. A.
    Zaslona, Z.
    Blaszczyk, R.
    Grzybowski, M. M.
    Rejczak, T.
    Cabaj, A.
    Dera, P.
    Lisiecki, K.
    Iwanowski, P.
    Charitos, T.
    Fung, S.
    ANNALS OF ONCOLOGY, 2023, 34 : S495 - S495
  • [34] Results of a first-in-human, dose-escalation phase 1 study of the ERK1/2 inhibitor ATG-017 in patients with advanced solid tumors
    Wahlroos, Sara
    Teng, Christina
    Tran, Ben
    Voskoboynik, Mark
    Gan, Hui Kong
    Spencer, Andrew
    Kudva, Anupa
    Song, Ming
    Lynch, Kevin
    Yu, Zhinuan
    Desai, Jayesh
    Lemech, Charlotte Rose
    Lifehouse, Chris O'Brien
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [35] A phase Ia/b first-in-human, open-label, dose-escalation, safety, PK and PD study of TP-0903 in solid tumours
    Sarantopoulos, J.
    Fotopoulos, G.
    Tsai, F. Y. -C.
    Beg, M. S.
    Adjei, A. A.
    Lou, Y.
    Seetharam, M.
    Villalona-Calero, M. A.
    Melear, J.
    Janat-Amsbury, M.
    Beever, H.
    Mouritsen, L.
    Wade, M.
    Bryan, B. V.
    Bearss, D. J.
    ANNALS OF ONCOLOGY, 2019, 30
  • [36] A first-in-human phase Ia/b, open-label, multicentre, dose-escalation study of BI 905711 in patients with advanced gastrointestinal cancers
    Harding, J.
    Hofheinz, R.
    Elez, E.
    Kuboki, Y.
    Geng, J.
    Schmohl, M.
    Dowling, E.
    Feng, Y.
    Rasco, D.
    ANNALS OF ONCOLOGY, 2020, 31 : S145 - S145
  • [37] A phase I, first-in-human, open-label, dose-escalation study of MGD013, a bispecific DART molecule binding PD-1 and LAG-3, in patients with unresectable or metastatic neoplasms.
    Luke, Jason J.
    Patel, Manish R.
    Hamilton, Erika Paige
    Chmielowski, Bartosz
    Ulahannan, Susanna Varkey
    Kindler, Hedy L.
    Bahadur, Shakeela Wazeen
    Clingan, Philip R.
    Mallesara, Girish
    Weickhardt, Andrew James
    Currence, Scott
    Xu, Linzhi
    Kaul, Sanjeev
    Chen, Francine
    Moore, Paul A.
    Bonvini, Ezio
    Sumrow, Brad
    Blumenschein, George
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [38] First-in-human phase I dose escalation study of MK-8033 in patients with advanced solid tumors
    Keedy, Vicki L.
    Lenz, Heinz-Josef
    Saltz, Leonard
    Whisenant, Jennifer G.
    Berlin, Jordan D.
    Camacho, Luis H.
    INVESTIGATIONAL NEW DRUGS, 2018, 36 (05) : 860 - 868
  • [39] A phase 1, first-in-human dose escalation study of ETC-159 in advanced or metastatic solid tumours
    Teneggi, V.
    Ng, M.
    Tan, D. S.
    Subbiah, V.
    Weekes, C.
    Diermayr, V.
    Ethirajulu, K.
    Yeo, P.
    Chen, D.
    Gan, S.
    Blanchard, S.
    Nellore, R.
    Lee, M. A.
    Hill, J.
    Virshup, D.
    Madan, B.
    Matter, A.
    ANNALS OF ONCOLOGY, 2016, 27
  • [40] First-in-human phase I dose escalation study of MK-8033 in patients with advanced solid tumors
    Vicki L. Keedy
    Heinz-Josef Lenz
    Leonard Saltz
    Jennifer G. Whisenant
    Jordan D. Berlin
    Luis H. Camacho
    Investigational New Drugs, 2018, 36 : 860 - 868
12345